Patents by Inventor Mathangi Krishnamurthy

Mathangi Krishnamurthy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cannabinoid derivatives, methods of making, and use thereof
    Publication number: 20070167514
    Abstract: 1?-substituted cannabinoid derivatives of delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, and delta-6a-10a-tetrahydrocannabinol that have affinity for the cannabinoid receptor type-1 (CB-1) and/or cannabinoid receptor type-2 (CB-2). Compounds having activity as either agonists or antagonists of the CB-1 and/or CB-2 receptors can be used for treating CB-1 or CB-2 mediated conditions.
    Type: Application
    Filed: January 26, 2007
    Publication date: July 19, 2007
    Inventors: Bob Moore, Antonio Ferreira, Mathangi Krishnamurthy
  • Cannabinoid derivatives, methods of making, and use thereof
    Patent number: 7169942
    Abstract: 1?-substituted cannabinoid derivatives of delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, and delta-6a-10a-tetrahydrocannabinol that have affinity for the cannabinoid receptor type-1 (CB-1) and/or cannabinoid receptor type-2 (CB-2). Compounds having activity as either agonists or antagonists of the CB-1 and/or CB-2 receptors can be used for treating CB-1 or CB-2 mediated conditions.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: January 30, 2007
    Assignee: University of Tennessee Research Foundation
    Inventors: Bob M. Moore, II, Antonio M. Ferreira, Mathangi Krishnamurthy
  • Cannabinoid derivatives, methods of making, and use thereof
    Publication number: 20040242593
    Abstract: 1′-substituted cannabinoid derivatives of delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, and delta-6a-10a-tetrahydrocannabinol that have affinity for the cannabinoid receptor type-1 (CB-1) and/or cannabinoid receptor type-2 (CB-2). Compounds having activity as either agonists or antagonists of the CB-1 and/or CB-2 receptors can be used for treating CB-1 or CB-2 mediated conditions.
    Type: Application
    Filed: May 20, 2004
    Publication date: December 2, 2004
    Inventors: Bob M. Moore, Antonio M. Ferreira, Mathangi Krishnamurthy